Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS - Related Studies

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS (STAR)

This study is currently recruiting participants.

Study NCT00573443. Last updated on November 11, 2008. Information provided by Avanir Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Pseudobulbar Affect (PBA)

2	Additional conditions recognized in this trial
		Amyotrophic Lateral Sclerosis
		Motor Neuron Disease
		Multiple Sclerosis

3	More general conditions related to this trial
		Autoimmune Diseases
		Autoimmune Diseases of the Nervous System
		Central Nervous System Diseases
		Demyelinating Autoimmune Diseases, CNS
		Demyelinating Diseases
		Immune System Diseases
		Nervous System Diseases
		Neurodegenerative Diseases
		Neuromuscular Diseases
		Spinal Cord Diseases

4	Interventions listed in this trial
		AVP-923

5	Additional drug interventions recognized in this trial
		Dextromethorphan

6	More general drug interventions related to this trial
		Antitussive Agents
		Central Nervous System Agents
		Excitatory Amino Acid Agents
		Excitatory Amino Acid Antagonists
		Molecular Mechanisms of Pharmacological Action
		Neurotransmitter Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Respiratory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Avanir Pharmaceuticals
		Kendle International